Genelux (GNLX) Competitors $2.49 +0.01 (+0.40%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GNLX vs. KMDA, TKNO, BTMD, CMPS, ACIU, JSPR, DSGN, LYEL, SAGE, and KODShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Kamada (KMDA), Alpha Teknova (TKNO), biote (BTMD), COMPASS Pathways (CMPS), AC Immune (ACIU), Jasper Therapeutics (JSPR), Design Therapeutics (DSGN), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Kamada Alpha Teknova biote COMPASS Pathways AC Immune Jasper Therapeutics Design Therapeutics Lyell Immunopharma Sage Therapeutics Kodiak Sciences Kamada (NASDAQ:KMDA) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is KMDA or GNLX more profitable? Kamada has a net margin of 9.92% compared to Genelux's net margin of 0.00%. Kamada's return on equity of 6.30% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Genelux N/A -105.05%-80.16% Does the media refer more to KMDA or GNLX? In the previous week, Kamada had 10 more articles in the media than Genelux. MarketBeat recorded 15 mentions for Kamada and 5 mentions for Genelux. Kamada's average media sentiment score of 0.00 beat Genelux's score of -0.63 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders & institutionals believe in KMDA or GNLX? 20.4% of Kamada shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate KMDA or GNLX? Kamada presently has a consensus price target of $14.50, indicating a potential upside of 149.14%. Genelux has a consensus price target of $18.25, indicating a potential upside of 632.93%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community believe in KMDA or GNLX? Kamada received 307 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 65.91% of users gave Kamada an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32165.91% Underperform Votes16634.09% GeneluxOutperform Votes14100.00% Underperform VotesNo Votes Which has more risk & volatility, KMDA or GNLX? Kamada has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Genelux has a beta of -1.85, suggesting that its share price is 285% less volatile than the S&P 500. Which has better valuation & earnings, KMDA or GNLX? Kamada has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$142.52M2.35$8.28M$0.2820.79Genelux$8K10,749.95-$28.30M-$0.95-2.62 SummaryKamada beats Genelux on 12 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.65M$6.43B$5.04B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-2.6210.10122.4217.58Price / Sales10,749.95243.351,179.2973.96Price / CashN/A22.1633.5632.51Price / Book3.415.474.694.68Net Income-$28.30M$153.61M$118.98M$225.87M7 Day Performance-11.39%-4.33%-2.45%-2.03%1 Month Performance-9.45%-8.62%-4.03%0.07%1 Year Performance-76.77%28.78%29.80%24.55% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.3298 of 5 stars$2.49+0.4%$18.25+632.9%-76.8%$85.65M$170,000.00-2.6210Gap UpKMDAKamada3.8063 of 5 stars$5.82-1.5%$14.50+149.1%+23.3%$339.70M$142.52M20.79360Analyst RevisionTKNOAlpha Teknova0.7125 of 5 stars$7.74+24.6%$5.00-35.4%+279.4%$331.04M$36.68M0.00240Gap UpHigh Trading VolumeBTMDbiote3.1909 of 5 stars$6.06-0.5%$8.39+38.4%+19.8%$330.19M$185.36M23.31194CMPSCOMPASS Pathways2.8433 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$325.68MN/A0.00120Short Interest ↓ACIUAC Immune2.2991 of 5 stars$3.24-0.9%$12.00+270.4%+0.0%$320.57M$16.48M-7.09140Positive NewsJSPRJasper Therapeutics2.6571 of 5 stars$20.98+1.4%$74.86+256.8%+227.3%$314.72MN/A-4.4320DSGNDesign Therapeutics1.7551 of 5 stars$5.48flat$7.00+27.7%+145.7%$310.28MN/A0.0040LYELLyell Immunopharma0.4947 of 5 stars$1.03-7.2%$1.00-2.9%-46.9%$309.93M$130,000.00-1.30270High Trading VolumeSAGESage Therapeutics4.2697 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M0.00690Analyst ForecastNews CoverageGap DownKODKodiak Sciences2.9773 of 5 stars$5.79+2.7%$3.50-39.6%+138.3%$296.80MN/A0.0090 Related Companies and Tools Related Companies Kamada Alternatives Alpha Teknova Alternatives biote Alternatives COMPASS Pathways Alternatives AC Immune Alternatives Jasper Therapeutics Alternatives Design Therapeutics Alternatives Lyell Immunopharma Alternatives Sage Therapeutics Alternatives Kodiak Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNLX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
